MetaCap

Abeona Therapeutics (ABEO) vs Korro Bio (KRRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Korro Bio (KRRO) has outperformed Abeona Therapeutics (ABEO) over the past year, gaining 93.9% versus a loss of 46.0%. Over five years, ABEO leads with a -86.7% price change compared with -95.7% for KRRO. Korro Bio is the larger company by market cap ($167.2 million vs $165.3 million), about 1.0 times the size.

Abeona Therapeutics converts more of its revenue into profit, with a net margin of 1223.1% versus -1834.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABEO-45.98%KRRO+93.95%
+175%+58%-60%
Nov 21, 20251 yearNov 20, 2026
ABEO-86.92%KRRO-95.95%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABEO versus KRRO key metrics
MetricABEOKRRO
Share price$2.42$12.18
Market cap$165.31M$167.18M
1-day change-1.22%-0.08%
YTD return-54.08%+52.06%
1-year return-45.98%+93.95%
5-year return-86.74%-95.67%
EPS (TTM)$-1.16$-8.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.82M$6.39M
Revenue growth (YoY)—+181.46%
Net income (latest FY)$71.18M$-117.26M
Gross margin73.68%—
Operating margin-1536.91%-1906.37%
Net margin1223.08%-1834.48%
52-week high$7.65$17.35
52-week low$2.09$5.20
Distance from 52-week high-68.37%-29.81%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+542.98%+76.52%
Average volume1.66M186.03K
Shares outstanding68.31M13.73M
Employees22658
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KRRO has outperformed ABEO by 139.9 percentage points over the past year.
  • Abeona Therapeutics is more profitable, keeping 1223.1 cents of every revenue dollar as net income versus -1834.5 cents for Korro Bio.

About Abeona Therapeutics

ABEO stock →

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.

Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees

About Korro Bio

KRRO stock →

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees

ABEO vs KRRO FAQ

Which is bigger, Abeona Therapeutics or Korro Bio?

Korro Bio (KRRO) is larger, with a market capitalization of $167.18M compared with $165.31M for Abeona Therapeutics (ABEO).

Which stock has performed better over the past year, ABEO or KRRO?

KRRO returned +93.95% over the past 12 months, compared with -45.98% for ABEO (price return, excluding dividends). Past performance does not predict future results.

Are Abeona Therapeutics and Korro Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons